Home Featured Page 251

Featured

Latest

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Field Trip Health Ltd. Announces Opening of Psychedelic-Enhanced Therapy Center in...

Psyched Wellness Signs Supply Agreement for Amanita Muscaria

Tryp Therapeutics Partners with Fluence for Psychotherapy Design

Mydecine Reports Full Year 2020 Financial Results and Provides Business Update

Champignon Brands Changes Name to Braxia Scientific to Reflect the Integration...

Psychedelic Bulletin: MindMed Uplists to Nasdaq; Cybin Targets Alcoholism; COMPASS Announces...

Ketanserin’s Contributions to Psychedelic Research

Should Society Legalize Psychedelics? A Breakdown of the Intelligence Squared Debate

PTSF57 – New Compounds, Psychedelic Business, and Neurogenesis

COMPASS Pathways announces pricing of public offering

1...250251252...295 Page 251 of 295

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Field Trip Health Ltd. Announces Opening of Psychedelic-Enhanced Therapy Center in...

Psyched Wellness Signs Supply Agreement for Amanita Muscaria

Tryp Therapeutics Partners with Fluence for Psychotherapy Design

Mydecine Reports Full Year 2020 Financial Results and Provides Business Update

Champignon Brands Changes Name to Braxia Scientific to Reflect the Integration...

Psychedelic Bulletin: MindMed Uplists to Nasdaq; Cybin Targets Alcoholism; COMPASS Announces...

Ketanserin’s Contributions to Psychedelic Research

Should Society Legalize Psychedelics? A Breakdown of the Intelligence Squared Debate

PTSF57 – New Compounds, Psychedelic Business, and Neurogenesis

COMPASS Pathways announces pricing of public offering

EDITOR PICKS

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY